Simultaneous treatment with benralizumab and ustekinumab in a patient with severe asthma and ulcerative colitis DOI Creative Commons
Lorenzo Carriera,

Roberto Barone,

Simone Ielo

et al.

Lung India, Journal Year: 2024, Volume and Issue: 42(1), P. 49 - 52

Published: Dec. 24, 2024

The burden of autoimmune diseases is rising worldwide. expansion the population patients eligible for severe asthma biological therapy we are seeing in clinical practice could lead to simultaneous use different monoclonal antibodies. We present case combination with ustekinumab and benralizumab a patient ulcerative colitis eosinophilic asthma. patient, already undergoing treatment colitis, began suffer from uncontrolled Since was administered, has not experienced any exacerbations requiring oral corticosteroids, emergency department visits, or hospital admissions, control symptoms respiratory function considerably improved. Twelve months after initiation combination, both well controlled, without side effects blood test abnormalities. To our knowledge, this one first reported cases simultaneously receiving

Language: Английский

Rethinking bronchiectasis as an inflammatory disease DOI

Merete Long,

Sanjay H. Chotirmall, Michal Shteinberg

et al.

The Lancet Respiratory Medicine, Journal Year: 2024, Volume and Issue: 12(11), P. 901 - 914

Published: July 3, 2024

Language: Английский

Citations

13

Increased risk of obstructive lung disease in inflammatory bowel disease: A population‐based cohort study DOI Creative Commons
Henrik Jacobsen, Anastasia Karachalia Sandri, Ulla Møller Weinreich

et al.

United European Gastroenterology Journal, Journal Year: 2024, Volume and Issue: 12(4), P. 477 - 486

Published: Jan. 6, 2024

Abstract Background and Aims Inflammatory bowel disease (IBD) is associated with manifestations in organs other than the gastrointestinal tract. In this study, we aimed to estimate odds of obstructive lung (OLD) before IBD onset risk OLD after onset. Methods a nationwide population‐based Danish cohort study from 1999 2018, individuals were identified using registries. Between 2003 2013, 24,238 matched 1:10 non‐IBD individuals. Logistic regression was used prevalence ratio for Time‐to‐event analysis performed explore sensitivity analysis, time‐to‐event repeated composite outcome separate outcomes, chronic pulmonary (COPD), asthma, bronchiectasis. Results Individuals 60% more likely have (adjusted ratio: 1.60, 95% confidence interval [CI]: 1.53–1.67). Furthermore, their 40% higher diagnosis hazard [aHR]: 1.43, CI: 1.37–1.49). The increased (aHR: 1.63, 1.53–1.73). Similar results found COPD asthma separately, whereas bronchiectasis 2‐fold 2.44, 1.91–3.11). Conclusion before‐ following an increased. We encourage physicians be vigilant symptoms persons OLD.

Language: Английский

Citations

6

Bidirectional association between asthma and inflammatory bowel disease: a systematic review and meta-analysis DOI Creative Commons

Yuyue Jiang,

Xuqing Huang,

Yan Wang

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 2(1)

Published: March 12, 2025

Language: Английский

Citations

0

Thirty-day outcomes of non-emergent colectomy for inflammatory bowel disease in patients with chronic obstructive pulmonary disease DOI
Renxi Li

Clinics and Research in Hepatology and Gastroenterology, Journal Year: 2024, Volume and Issue: 48(8), P. 102445 - 102445

Published: Aug. 6, 2024

Language: Английский

Citations

0

Increased risk of chronic respiratory disease among individuals with inflammatory bowel disease in a prospective cohort study DOI
Lintao Dan,

Ying Xie,

Tian Fu

et al.

The American Journal of Medicine, Journal Year: 2024, Volume and Issue: 138(1), P. 42 - 50.e5

Published: Oct. 5, 2024

Language: Английский

Citations

0

Simultaneous treatment with benralizumab and ustekinumab in a patient with severe asthma and ulcerative colitis DOI Creative Commons
Lorenzo Carriera,

Roberto Barone,

Simone Ielo

et al.

Lung India, Journal Year: 2024, Volume and Issue: 42(1), P. 49 - 52

Published: Dec. 24, 2024

The burden of autoimmune diseases is rising worldwide. expansion the population patients eligible for severe asthma biological therapy we are seeing in clinical practice could lead to simultaneous use different monoclonal antibodies. We present case combination with ustekinumab and benralizumab a patient ulcerative colitis eosinophilic asthma. patient, already undergoing treatment colitis, began suffer from uncontrolled Since was administered, has not experienced any exacerbations requiring oral corticosteroids, emergency department visits, or hospital admissions, control symptoms respiratory function considerably improved. Twelve months after initiation combination, both well controlled, without side effects blood test abnormalities. To our knowledge, this one first reported cases simultaneously receiving

Language: Английский

Citations

0